



# Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

Sonia Pernas<sup>1\*</sup>, Anna Petit<sup>2</sup>, Fina Climent<sup>2</sup>, Laia Paré<sup>3</sup>, J. Perez-Martin<sup>4</sup>, Luz Ventura<sup>1</sup>, Milana Bergamino<sup>1</sup>, Patricia Galván<sup>3</sup>, Catalina Falo<sup>1</sup>, Idoia Morilla<sup>1</sup>, Adela Fernandez-Ortega<sup>1</sup>, Agostina Stradella<sup>1</sup>, Montse Rey<sup>5</sup>, Amparo Garcia-Tejedor<sup>6</sup>, Miguel Gil-Gil<sup>1</sup> and Aleix Prat<sup>3\*</sup>

## OPEN ACCESS

### Edited and reviewed by:

Michael Grant,  
Medical University of Vienna, Austria

### \*Correspondence:

Sonia Pernas  
spernas@iconcologia.net  
Aleix Prat  
alprat@clinic.cat

### Specialty section:

This article was submitted to  
Women's Cancer,  
a section of the journal  
Frontiers in Oncology

Received: 21 August 2019

Accepted: 11 September 2019

Published: 25 September 2019

### Citation:

Pernas S, Petit A, Climent F, Paré L, Perez-Martin J, Ventura L, Bergamino M, Galván P, Falo C, Morilla I, Fernandez-Ortega A, Stradella A, Rey M, Garcia-Tejedor A, Gil-Gil M and Prat A (2019) Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution. *Front. Oncol.* 9:967. doi: 10.3389/fonc.2019.00967

<sup>1</sup> Department of Medical Oncology-Breast Cancer Unit, Institut Català d'Oncologia (ICO)-H.U.Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain, <sup>2</sup> Department of Pathology-Breast Cancer Unit, Institut Català d'Oncologia (ICO)-H.U.Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain, <sup>3</sup> Department of Medical Oncology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain, <sup>4</sup> Clinical Research Unit, Institut Català d'Oncologia (ICO)-L'Hospitalet, Barcelona, Spain, <sup>5</sup> Department of Pharmacy, Institut Català d'Oncologia (ICO)-L'Hospitalet, Barcelona, Spain, <sup>6</sup> Department of Gynecology-Breast Cancer Unit, Institut Català d'Oncologia (ICO)-H.U.Bellvitge-Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Universitat de Barcelona, Barcelona, Spain

**Keywords:** breast cancer, HER2, pathological complete response, gene expression, molecular intrinsic subtype, residual disease, paired samples

## A Corrigendum on

### PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

by Pernas, S., Petit, A., Climent, F., Paré, L., Perez-Martin, J., Ventura, L., et al. (2019). *Front. Oncol.* 9:707. doi: 10.3389/fonc.2019.00707

In the original article, there was a mistake in **Figure 1** as published. The colors of the labels used for **Figures 1B,D** were incorrect. pCR should be in red and non-pCR should be in blue. The corrected **Figure 1** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2019 Pernas, Petit, Climent, Paré, Perez-Martin, Ventura, Bergamino, Galván, Falo, Morilla, Fernandez-Ortega, Stradella, Rey, Garcia-Tejedor, Gil-Gil and Prat. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

